Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Masitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 13/20 | 0.94 |
| ▸ | PDGFRA known ✓ | P16234 | 4/20 | 0.94 |
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.94 |
| ▸ | ABL1 | P00519 | 19/20 | 0.94 |
| ▸ | BCR | P11274 | 14/20 | 0.94 |
| ▸ | ABL2 | P42684 | 7/20 | 0.94 |
| ▸ | SRC | P12931 | 3/20 | 0.94 |
| ▸ | EGFR | P00533 | 2/20 | 0.94 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.94 |
| ▸ | LCK | P06239 | 2/20 | 0.94 |
| ▸ | FYN | P06241 | 2/20 | 0.94 |
| ▸ | CSF1R | P07333 | 2/20 | 0.94 |
| ▸ | LYN | P07948 | 2/20 | 0.94 |
| ▸ | FGR | P09769 | 2/20 | 0.94 |
| ▸ | BRAF | P15056 | 2/20 | 0.94 |
| ▸ | NQO2 | P16083 | 2/20 | 0.94 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.94 |
| ▸ | FRK | P42685 | 2/20 | 0.94 |
| ▸ | BLK | P51451 | 2/20 | 0.94 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL2297143 | 1.00 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL1096348 | 1.00 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL717239 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL29355443 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL29353195 | 0.97 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL5515053 | 0.93 | ABL1 (0.84) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL3301373 | 0.93 | ABL1 (0.91) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL16085058 | 0.91 | ABL1 (0.89) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL717173 | 0.91 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL17177780 | 0.91 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061371-B1 | MASITINIB FOR THE TREATMENT OF SICKLE CELL DISEASE | AB SCIENCE (FR) | 2025-02-19 | — | — | EP | claimed |
| EP-4175639-B1 | MASITINIB FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | AB SCIENCE (FR) | 2023-10-25 | — | — | EP | claimed |
| EP-3601278-B1 | CRYSTALLINE FORM OF MASITINIB | SANDOZ AG (CH) | 2022-10-26 | — | — | EP | claimed |
| EP-4537844-A1 | PROPHYLACTIC OR THERAPEUTIC AGAINST EXACERBATION OR RECURRENCE OF CANCER, AND SCREENING METHOD THEREFOR | Keio University (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023238939-A1 | PROPHYLACTIC OR THERAPEUTIC AGAINST EXACERBATION OR RECURRENCE OF CANCER, AND SCREENING METHOD THEREFOR | 慶應義塾 | 2023-12-14 | — | — | WO | disclosed |